I do think it’s possible that some investors have unloaded some common to buy the lower priced Cs, only because I know of a few shareholder friends who did that several years ago. But I don’t begrudge anyone doing this as it has been a way to raise much needed funding for the company and to keep them going… which is in my best interests, and presumably, anyone who is heavily invested in Northwest.
As to your question on the small financing amounts over the years… back in 2015, 16, 17 and at least 18… they slowly moved from using PFS as the primary to instead using the trial’s own OS. And they were trying to extend the trial out long enough to where they could get a stat sig OS (because so many of the trial participants were living longer). But (and I’m assuming here) I don’t think the theoretical blinded (yes, blinded… no matter what ex and others claim) numbers were adding up to guarantee a sure stat sig outcome. And because they kept hoping that the next blinded look they did would be last one, they limped along with the small financings, that have obviously turned into something that has likely contributed to the downward trend. But I also believe that there have been some serious hanky panky on the part of some scum of the earth shorts over these past years, and my hope is they are either revealed (better yet, financially destroyed) in the lawsuit, or that the company gets a significant pound of flesh out of them to help recoup much of the losses that are also due to the extensive and aggressive shorting.
Market Data 
Markets 
AI
